Attention to hormone receptor (HR) function in breast cancer has largely focused on estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth receptor 2 (HER2). The success of therapies targeted at these receptors has led to interest in androgen receptor (AR), a member of the steroid receptor (SR) subfamily, as another possible target in breast cancer therapy. Immunohistochemical studies have revealed an independent prognostic value of AR in ERa-positive breast cancer (Castellano et al. 2010) , and the prognosis of AR-positive/ERa-negative tumors has been reported to be better than that of AR-negative one (Kuenen-Boumeester et al. 1996) . These studies have revealed that AR plays an inherent role in breast cancer cell signaling. Much effort has been invested in elucidating the mechanism of action of AR in human epithelial cells. This includes research on posttranslational modifications, including phosphorylation, ubiquitination, acetylation, and sumoylation (Ward & Weigel 2009 ). Among these, AR phosphorylation has been shown to play a critical role in signal transduction (Lin et al. 2001) , and a large number of phosphorylation sites have been identified, with the majority near the N-terminus. AR is phosphorylated at serine-213/210 (pAR 213/210 ) by the phosphatidylinositol 3-kinase/Akt signaling pathway (Wen et al. 2000) , which modulates AR transcriptional activity (Lin et al. 2001 (Lin et al. , 2003 . The objectives of the current study were to examine AR and pAR 213/210 levels in a large series of breast cancers and to assess the impact of AR and pAR 213/210 expression on relapsefree survival (RFS) and breast cancer-specific survival (BCSS) in all breast cancers. A total of 379 consecutive patients (median age 58 years (range 21-93)) with invasive breast cancer were enrolled from a database that included patient and tumor characteristics, as well as the pathology findings at the initial and relapse diagnoses. (Fig. 1A) . All samples were scored using a histoscore (HS), multiplying the percentage (0-100) of cells stained at a given intensity by the staining intensity score (IS) (0, none; 1, weak; 2, moderate; and 3, intense). AR and nuclear and cytoplasmic expression of pAR 213/210 were observed in benign breast tissue. However, the patterns of both AR and phosphorylated AR expression were increased in breast cancers compared with benign controls (Ren et al. 2013) . Compared with other studies in which AR expression was dichotomized as having positive cells or not, we used a HS (O10) for AR and a IS (R2) for pAR 213/210 as a cutoff point, which we believe more accurately reflects the expression of AR and its phosphorylation status in breast cancer (Fig. 1A) . The median HS was 126 in nuclear AR, 112 in nuclear pAR 213/210 , and zero in cytoplasmic pAR 213/210 (Fig. 1B) .
Nuclear staining of AR was observed in 76% of the samples. The correlation of AR expression and patient characteristics is summarized in Tables 1 and 2 ).
In the analysis of RFS, local recurrences and distant metastases were considered as an event. Forty-seven (12.4%) patients experienced breast cancer relapse and 330 (87.1%) were relapse free at the last follow-up. A total of 28 patients died of breast cancer, which were regarded as events when analyzing BCSS. AR-positive patients were associated with prolonged RFS (P!0.0001) and BCSS (P!0.0001) (Figs 2A and 3A) , which was tested by the Kaplan-Meier method and verified by the log-rank (Mantel-Cox) test. Analyzed by subtype, AR positivity was associated with prolonged RFS and BCSS in the HR-positive/HER2-negative group (PZ0.020 and PZ0.009 respectively) and in the HR-negative/HER2-negative group (PZ0.016 and PZ0.017 respectively), but there was no statistical difference in survival associated with AR positivity in the HER2-positive group (Figs 2C, E, G and 3C, E, G) was not a significant prognostic parameter for either RFS or BCSS. Clinical and molecular studies involving AR in breast cancer over the past decade, and in particular over the last year, have reinvigorated interest. However, the role of the androgen-signaling pathway in breast cancer etiology and progression remains largely unknown. This is the first retrospective study to investigate the changes that occur to multiple members of the AR pathway in breast cancer, and in particular, to test whether phosphorylation of AR is associated with patient outcome measures. Site-specific phosphorylation of SRs has been shown to be modulated by a wide variety of kinases depending on the cellular context, affecting hormone sensitivity, receptor stability and localization, DNA binding, and cofactor interaction (Ward & Weigel 2009 ). Phosphorylation of AR at serines 16, 81, 256, 308, 424 , and 650 was reported to be increased in response to androgen, while serine 94 was constitutively phosphorylated (Gioeli et al. 2002 , Black et al. 2004 . AR phosphorylation is also induced by MAPK (serine-threonine kinase) and AKT, which sensitizes AR to low levels of DHT, allowing low levels of androgens, or alternative steroids, to induce translocation of the AR to the nucleus, facilitating gene activation. Of note, AKT can be activated via the PI3 kinase pathway, which is involved in cell growth, adhesion, and migration in many tumors (Lin et al. 2003) and specifically phosphorylates AR at Ser210 and Ser790 (Wen et al. 2000) . In prostate cancer patients, pAR 213/210 leads to the development of hormone refractory disease and worse outcomes (McCall et al. 2008) .
Although one group reported correlation between pAR 213/210 and clinicopathological parameters in breast cancer (Ren et al. 2013) , its significance as a prognostic marker remains unclear. Our data indicated that AR was a prognostic factor and the phosphorylated AR was strongly correlated with a better outcome in AR-positive patients. With more data regarding the presence of AR and AR signaling pathways in breast cancer, researchers have the opportunity to develop more efficacious targeted therapies.
In conclusion, our study demonstrates that AR and pAR 213/210 can be independent prognostic markers. Furthermore, further understanding of AR phosphorylation can provide new therapeutic targets in breast cancer. 
